Impact of Brokerage Rating on BioMarin Pharmaceutical Inc.(BMRN)

Many BioMarin Pharmaceutical Inc.(BMRN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. BioMarin Pharmaceutical was Initiated by Morgan Stanley on Feb 7, 2017 to Overweight, Price Target of the shares are set at $110.BioMarin Pharmaceutical was Resumed by Credit Suisse to Outperform on Jan 23, 2017. BioMarin Pharmaceutical was Initiated by Gabelli & Co on Dec 8, 2016 to Buy, Price Target of the shares are set at $109.

Company has reported several Insider transactions to the SEC, on Jan 27, 2017, Jean Jacques Bienaime (Chief Executive Officer) sold 10,000 shares at 84.22 per share price.On Jan 10, 2017, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 5,000 shares at 90.00 per share price.On Nov 29, 2016, Henry J Fuchs (President, Worldwide R&D) sold 15,000 shares at 87.40 per share price.

BioMarin Pharmaceutical Last issued its quarterly earnings results on Oct 27, 2016. The company reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $-0.08. The company had revenue of $279.90 million for the quarter, compared to analysts expectations of $289.36 million. The companys revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.60 EPS.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.5 by 17 Brokerage Firm. 11 Wall Street Firms have rated the stock as a strong buys. 3 stock experts have also suggested a buy rating. 3 Brokerage Firms have advised hold.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): 18 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $114 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). However, the stock price could fluctuate by $ 14.41 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $150 price target with the lower price estimate is calculated at $84

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose 0.33% or 0.3 points on Tuesday and made its way into the gainers of the day. After trading began at $90.46 the stock was seen hitting $91.6 as a peak level and $90.09 as the lowest level. The stock ended up at $91.19. The daily volume was measured at 787,167 shares. The 52-week high of the share price is $102.49 and the 52-week low is $70.08. The company has a market cap of $15,684 million.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarins lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

BioMarin

Share this post

Post Comment